The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
MMP-9 Inhibition: a Therapeutic Strategy in Ischemic Stroke
Open accessAbstract
Ischemic stroke is a leading cause of disability worldwide. In cerebral ischemia there is an enhanced expression of matrix metallo-proteinase-9 (MMP-9), which has been associated with various complications including excitotoxicity, neuronal damage, apoptosis, blood-brain barrier (BBB) opening leading to cerebral edema, and hemorrhagic transformation. Moreover, the tissue plasminogen activator (tPA), which is the only US-FDA approved treatment of ischemic stroke, has a brief 3 to 4 h time window and it has been proposed that detrimental effects of tPA beyond the 3 h since the onset of stroke are derived from its ability to activate MMP-9 that in turn contributes to the breakdown of BBB. Therefore, the available literature suggests that MMP-9 inhibition can be of therapeutic importance in ischemic stroke. Hence, combination therapies of MMP-9 inhibitor along with tPA can be beneficial in ischemic stroke. In this review we will discuss the current status of various strategies which have shown neuroprotection and extension of thrombolytic window by directly or indirectly inhibiting MMP-9 activity. In the introductory part of the review, we briefly provide an overview on ischemic stroke, commonly used models of ischemic stroke and a role of MMP-9 in ischemia. In next part, the literature is organized as various approaches which have proven neuroprotective effects through direct or indirect decrease in MMP-9 activity, namely, using biotherapeutics, involving MMP-9 gene inhibition using viral vectors; using endogenous inhibitor of MMP-9, repurposing of old drugs such as minocycline, new chemical entities like DP-b99, and finally other approaches like therapeutic hypothermia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hu, Q., Chen, C., Yan, J., Yang, X., Shi, X., Zhao, J., Lei, J., Yang, L., Wang, K., Chen, L., et al. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.11.007 · Cited by 96
RetractedTissue Plasminogen Activator for Acute Ischemic Stroke
(1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332401 · Cited by 11,654
How Matrix Metalloproteinases Regulate Cell Behavior
Sternlicht, M. D., & Werb, Z. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.463 · Cited by 3,959
Benardete, E. A., & Nair, A. K. (2015) · Cerebrovascular Diseases Extra · doi:10.1159/000370060 · Cited by 2,546
The influence of immaturity on hypoxic‐ischemic brain damage in the rat
Rice, J. E., Vannucci, R. C., & Brierley, J. B. (1981) · Annals of Neurology · doi:10.1002/ana.410090206 · Cited by 2,134
Inflammatory mechanisms in ischemic stroke: therapeutic approaches
Lakhan, S. E., Kirchgessner, A., & Hofer, M. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-97 · Cited by 1,072
Asahi, M., Wang, X., Mori, T., Sumii, T., Jung, J.-C., Moskowitz, M. A., Fini, M. E., & Lo, E. H. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-19-07724.2001 · Cited by 1,004
Tetracyclines: Nonantibiotic properties and their clinical implications
Sapadin, A. N., & Fleischmajer, R. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.10.004 · Cited by 768
Romanic, A. M., White, R. F., Arleth, A. J., Ohlstein, E. H., & Barone, F. C. (1998) · Stroke · doi:10.1161/01.str.29.5.1020 · Cited by 739
Role of matrix metalloproteinases in delayed cortical responses after stroke
Zhao, B.-Q., Wang, S., Kim, H.-Y., Storrie, H., Rosen, B. R., Mooney, D. J., Wang, X., & Lo, E. H. (2006) · Nature Medicine · doi:10.1038/nm1387 · Cited by 702
Cited by
Neuroinflammation: friend and foe for ischemic stroke
Jayaraj, R. L., Azimullah, S., Beiram, R., Jalal, F. Y., & Rosenberg, G. A. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1516-2 · Cited by 1,428
Is there new hope for therapeutic matrix metalloproteinase inhibition?
Vandenbroucke, R. E., & Libert, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4390 · Cited by 832
Brkic, M., Balusu, S., Libert, C., & Vandenbroucke, R. E. (2015) · Mediators of Inflammation · doi:10.1155/2015/620581 · Cited by 205
The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders
Wen, T. H., Binder, D. K., Ethell, I. M., & Razak, K. A. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00270 · Cited by 170
Ritzel, R. M., Doran, S. J., Glaser, E. P., Meadows, V. E., Faden, A. I., Stoica, B. A., & Loane, D. J. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.02.010 · Cited by 156
Metadata
- Authors
- Chaturvedi, M., & Kaczmarek, L.
- Venue
- Molecular Neurobiology
- Published
- 2013-09-12
- Volume
- 49
- Issue
- 1
- Pages
- 563-573
- ISSN
- 0893-7648 (ISSN-L)
- 1559-1182
- OpenAlex
- W2061250188
- Cited by
- 296
- References
- 102
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MMP-9 Inhibition: a Therapeutic Strategy in Ischemic Stroke. https://app.cochat.ai/papers/10.1007/s12035-013-8538-z
- The paper
- Chaturvedi, M., & Kaczmarek, L. (2014). MMP-9 Inhibition: a Therapeutic Strategy in Ischemic Stroke. Molecular Neurobiology. https://doi.org/10.1007/s12035-013-8538-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.